In 2007 the global vaccine market was $16.3 billion and, with an anticipated growth rate of 16.5% is expected to reach at least $21.1 billion by 2010. The development of vaccines against classic “emerging infections” such as cryptosporidiosis is recognized as a key activity by CDC, USA.
In developing countries cryptosporidiosis is a major cause of death in otherwise healthy children as well as in AIDS patients. The global HIV prevalence represents a total of 33.2 million people worldwide in 2007, rising from 29.0 million in 2001.
The categorization of cryptosporidiosis as a Category B Bioterrorism Disease by the CDC creates a novel market for a vaccine product when governments stockpile drugs for intervention . The PlantForm vaccine is a novel product.
